Advances in cancer nanotheranostics for experimental and personalized medicine / edited by Prof. Dr. Yusuf Tutaru.

Includes bibliographical references.

Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Cancer Nanotheranostics -- Ezgi Nurdan Yenilmez Tunoglu1, Berçem Yeman1, Merve Biçen1, Servet Tunoglu2, Yousef Rasmi3 and Yusuf Tutar1,4,* -- INTRODUCTION -- Oncology in Brief -- Genomic Era -- Transcriptome Analysis -- Epigenomic Regulations -- Proteomic Approaches -- Metabolomics -- Targeted Delivery Through NPs -- Stem Cells and Cancer -- Cancer Treatment with Mesenchymal Stem Cells -- iPSCs: Return to The Past -- FUTURE PERSPECTIVES -- CONSENT FOR PUBLICATION

CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Tumor Microenvironment: A Critical Determinant in Regulating Tumor Progression and Metastasis -- Raghda Ashraf Soliman1, Rana Ahmed Youness1,* and Mohamed Zakaria Gad2,* -- THE TUMOR MICROENVIRONMENT -- CELLULAR COMPONENTS OF THE TME -- Tumor Infiltrating Lymphocytes -- T-lymphocytes -- B-lymphocytes -- Natural Killer (NK) Cells -- Myeloid Derived Suppressor Cells (MDSCs) -- Tumor Associated Macrophages (TAMs) -- Tumor Associated Neutrophils (TANs) -- Dendritic Cells (DCs) -- Adipocytes -- Cancer Associated Fibroblasts (CAFs)

Non-cellular Components -- Cytokines -- Chemokines -- Growth Factors -- ECM Remodeling Enzymes -- TME and Therapy -- Targeting Tumor Microenvironment -- Targeting TME Hypoxia -- Targeting Inflammation -- Targeting Angiogenesis -- Targeting Tumor Residence Cells -- Targeting CAFs -- Remodeling/Targeting ECM -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Nanotechnology in Cancer Theranostics -- Asmaa Mostafa1,2 and Matthias Bartneck1,* -- 1. NANOMEDICINES AND THERANOSTICS -- 1.1. Putative Anti-cancer Nanomedicines and their Biodistribtion

1.2. Theranostic Medicines -- 1.3. Nanomedicines for Passive and Active Targeting -- 1.4. How Omics Data can be Used to Develop Improved (nano- ) Drugs -- 1.5. Strategies to Localize Drug Delivery -- 1.6. Therapeutic Options of Small Non-coding RNA -- 2. IMMUNE CELL-DIRECTED THERAPIES -- 2.1. Lymphoid Cells are in the Focus of Cancer Therapy -- 2.2. Evolving Therapies Targeting Macrophages and Other Myeloid Cells -- CONCLUSIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Nanotheranostics in Gene Therapy

Beatriz B. Oliveira, Alexandra R. Fernandes and Pedro V. Baptista* -- 1. GENE DELIVERY FOR CANCER THERAPY -- 2. NANOTECHNOLOGY IN GENE DELIVERY -- 2.1. Considering the Biological Barriers -- 2.2. Gene Delivery Systems and Applications -- 2.3. Targeting Strategies -- Antibodies -- Peptides -- Small Molecules -- 3. NANOTHERANOSTICS CONCEPTS FOR GENE DELIVERY -- 3.1. Imaging Techniques -- Optical Imaging -- Computed Tomography -- Magnetic Resonance Imaging -- Radionuclide Imaging (PET/SPECT) -- 3.2. Therapeutic Nucleic Acids -- Small Interfering RNA (siRNA) -- MicroRNAs (miRNAs)

Nanotheranostics is a recent medical field which integrates diagnostic imaging protocols and therapeutic functions to monitor real time drug release in the body and distribution to the target site. The combined processes allow technicians to observe the effectiveness of a specifically designed drug candidate and predict its possible side effects. All these features help clinicians in optimizing treatment options for cancer and other diseases for the individual patient. Current research is tailored to individual therapy because each drug may display a variety of responses depending on variation.

eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide